The American Society of Clinical Oncology and the Association of Community Cancer Centers have jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion in cancer clinical trials.
Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network.
Researchers at the American Cancer Society have found that after the implementation of the Affordable Care Act, adults in the United States with Limited English Proficiency had consistently worse access to medical care, including cancer prevention services, than adults without LEP.
A gene that UVA Health researchers discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.
A study published in Blood Advances found that women make up 37.7% of all speakers at hematology and medical oncology board review lectures.
FDA accepted for review a Biologics License Application from ImmunityBio, Inc. for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Merck has paid $35 million Kelun-Biotech to Merck for the exclusive rights to develop, manufacture and commercialize an investigational antibody drug conjugate for treatment of solid tumors.
Mission Bio Inc. has created the first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
NRG Oncology has appointed the following committee chairs and vice chairs.
Fox Chase Cancer Center and Temple Health have named the following people to the Division of Urology and Urologic Oncology.
